Effective 2/12/25, the US Food and Drug Administration (FDA) has approved IZERVAY for use beyond 12 months.¹

IZERVAY is approved for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).¹

For questions or to learn more, please reach out to your Astellas Account Manager.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

•	IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

•	Endophthalmitis and Retinal Detachments

○

Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

•	Neovascular AMD

○

In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

•	Increase in Intraocular Pressure

○	Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

•	Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

Please click here for IZERVAY full Prescribing Information.

Reference: 1. Izervay. Package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2025.

For important state pricing disclosure information, click here.

Astellas Pharma US, Inc.; 2375 Waterview Drive; Northbrook, IL 60062

US-AP-2400548 03/25

This content is sponsored by Astellas, and Specialty Practice Network has not independently reviewed or verified the information provided by Astellas.

This email was sent to karleigh.bard-marsh@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | Specialty Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.